Immunome, Inc.
Veridion Score
Composite trend over time
Why is IMNM moving today?
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IMNM.
IMNM insider activity
Immunome, Inc.
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for IMNM.
IMNM contract awards, year to date.
Public federal awards linked to this ticker.
IMNM lobbying filings, year to date.
Registered lobbying filings matched to Immunome, Inc..